Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: The bezafibrate infarction prevention (BIP) study

Circulation

Volumn 102, Issue 1, 2000, Pages 21-27

  Behar, S ^a   Brunner, D ^a   Kaplinsky, E ^a   Mandelzweig, L ^a   Benderly, M ^a  

^a SHEBA MEDICAL CENTER   (Israel)

Author keywords

Bezafibrate; Cardiovascular diseases; Lipids; Lipoproteins, HDL; Prevention; Triglycerides

Indexed keywords

BEZAFIBRATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY RISK; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEART INFARCTION; HUMAN; HYPERLIPIDEMIA; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK MANAGEMENT; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0034604225     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.102.1.21     Document Type: Article

References (29)

1. Brunner D, Altman S, Loebl K, et al. Alpha-cholesterol percentages in coronary patients with and without increased total serum cholesterol levels and in healthy controls. J Atheroscler Res. 1962;2:424-437.
2. Franzen J, Johansson BW, Gustfson A. Reduced high density lipoproteins as a risk factor after acute myocardial infarction. Acta Med Scand. 1987;221: 357-362.
3. Pekkanen J, Linn S, Heiss G, et al. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. N Engl J Med. 1990;322:1700-1707.
4. Goldbourt U, Yaari S, Medalie JH. Isolated low HDL cholesterol as a risk factor for coronary heart disease mortality: a 21-year follow-up of 8000 men. Arterioscler Thromb Vasc Biol. 1997;17:107-113.
5. Brunner D, Altman S, Lobel K, et al. Serum cholesterol and triglycerides in patients suffering from ischemic disease and in healthy subjects. Atherosclerosis. 1977;28:197-204.
6. Austin MA. Plasma triglyceride and coronary heart disease. Arterioscler Thromb. 1991;11:2-14.
7. Assmann G, Schulte H, Cullen P. New and classical risk factors: the Munster Heart Study (PROCAM). Eur J Med Res. 1997;2:237-242.
8. Austin MA. Plasma triglyceride as a risk factor for coronary heart disease: the epidemiologic evidence and beyond. Am J Epidemiol. 1989;129:249-259.
9. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk. 1996;3:213-219.
10. Berge KG, Canner PL. Coronary drug project: experience with niacin: Coronary Drug Project Research Group. Eur J Clin Pharmacol. 1991;40(suppl 1):S49-S51.
11. Manninen V, Tenkanen L, Koskinen P, et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study: implications for treatment. Circulation. 1992;85:37-45.
12. Shepherd J, Cobbe SM, Ford I, et al, for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333: 1301-1307.
13. The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) study group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349-1357.
14. Sacks FM, Pfeffer MA, Moye LA, et al, for the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001-1009.
15. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
16. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS: Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279:1615-1622.
17. The Bezafibrate Infarction Prevention (BIP) study group. Lipids and lipoproteins in symptomatic coronary heart disease: distribution, intercorrelations, and significance for risk classification in 6700 men and 1500 women. Circulation. 1992;86:839-848.
18. Goldbourt U, Behar S, Reicher-Reiss H, et al, for the Bezafibrate Infarction Prevention Study Group. Rationale and design of a secondary prevention trial of increasing serum high-density lipoprotein cholesterol and reducing triglycerides in patients with clinical manifest atherosclerotic heart disease (the Bezafibrate Infarction Prevention Trial). Am J Cardiol. 1993;71:909-915.
19. Vu-Dac N, Schoonjans K, Laine B, et al. Negative regulation of the human apolipoprotein A-I promoter by fibrates can be attenuated by the interaction of the peroxisome proliferator-activated receptor with its response element. J Biol Chem. 1994;269:31012-31018.
20. Auwerx J, Schoonjans K, Fruchart JC, et al. Regulation of triglyceride metabolism by PPARs: fibrates and thiazolidinediones have distinct effects. Atheroscler Thromb. 1996;3:81-89.
21. Auwerx J, Schoonjans K, Fruchart JC, et al. Transcriptional control of triglyceride metabolism: fibrates and fatty acids change the expression of the LPL and apoC-III genes by activating the nuclear receptor PPAR. Atherosclerosis. 1995;124(suppl):S29-S37.
22. Staels B, Dallongeville J, Auwerx J, et al. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation. 1998;98:2088-2093.
23. Goldbourt U, Brunner D, Behar S, et al, for the BIP study group. Baseline characteristics of patients participating in the Bezafibrate Infarction Prevention (BIP) study. Eur Heart J. 1998;19(suppl H):H42-H47.
24. Friedewald WT, Levy RI, Frederickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
25. SAS Institute Inc. SAS/STAT User's Guide. Version 6. 4th ed. Cary, NC: SAS Institute, Inc; 1987.
26. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults, National Cholesterol Education Program. Second report of the Expert Panel on Detection. Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation. 1994;89: 1329-1445.
27. Rubins H, Robins SJ, Collins D, et al, for the Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med. 1999;341:410-418.
28. Frick MH, Syvanne M, Nieminen MS, et al, for the Lopid Coronary Angiography Trial (LOCAT) study group. Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Circulation. 1997;96:2137-2143.
29. Ericsson CG, Hamsten A, Nilsson J, et al. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male post-infarction patients. Lancet. 1996;347:849-853.